Literature DB >> 2012712

Pharmacokinetics of gentamicin in neonatal patients supported with extracorporeal membrane oxygenation.

P J Munzenberger1, N Massoud.   

Abstract

This analysis of gentamicin pharmacokinetics involved 15 neonates supported by extracorporeal membrane oxygenation (ECMO). Two sets of blood samples were obtained from each neonate while supported by ECMO. The mean volume of distribution, elimination half-life, and clearance calculated from the first set of samples were 0.62 liters/kg, 7.6 hours, and 1.17 ml/kg/minute, respectively. Mean values from the second set of samples were 0.61 liters/kg, 7.9 hours and 0.99 ml/kg/minute, respectively. There were no statistical differences (p greater than 0.05) between the pharmacokinetics calculated from the first and second set of samples. A comparison of our results with those of others involving neonates not supported by ECMO failed to demonstrate any major impact of ECMO on the pharmacokinetics of gentamicin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2012712     DOI: 10.1097/00002480-199101000-00006

Source DB:  PubMed          Journal:  ASAIO Trans        ISSN: 0889-7190


  15 in total

Review 1.  Drugs pharmacokinetics during veno-venous extracorporeal membrane oxygenation in pediatrics.

Authors:  Matteo Di Nardo; Enno Diederick Wildschut
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

Review 2.  Optimising drug dosing in patients receiving extracorporeal membrane oxygenation.

Authors:  Vesa Cheng; Mohd-Hafiz Abdul-Aziz; Jason A Roberts; Kiran Shekar
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

3.  Pharmacokinetics and safety of fluconazole in young infants supported with extracorporeal membrane oxygenation.

Authors:  Kevin M Watt; Daniel K Benjamin; Ira M Cheifetz; Ganesh Moorthy; Kelly C Wade; P Brian Smith; Kim L R Brouwer; Edmund V Capparelli; Michael Cohen-Wolkowiez
Journal:  Pediatr Infect Dis J       Date:  2012-10       Impact factor: 2.129

Review 4.  Innovative clinical trial design for pediatric therapeutics.

Authors:  Matthew M Laughon; Daniel K Benjamin; Edmund V Capparelli; Gregory L Kearns; Katherine Berezny; Ian M Paul; Kelly Wade; Jeff Barrett; Phillip Brian Smith; Michael Cohen-Wolkowiez
Journal:  Expert Rev Clin Pharmacol       Date:  2011-09       Impact factor: 5.045

Review 5.  Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation.

Authors:  Kevin Watt; Jennifer S Li; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  J Cardiovasc Pharmacol       Date:  2011-08       Impact factor: 3.105

Review 6.  Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole.

Authors:  Kevin Watt; Paolo Manzoni; Michael Cohen-Wolkowiez; Stefano Rizzollo; Elena Boano; Evelyne Jacqz-Aigrain; Daniel K Benjamin
Journal:  Curr Drug Metab       Date:  2013-02       Impact factor: 3.731

Review 7.  Pharmacokinetics and Dosing of Anti-infective Drugs in Patients on Extracorporeal Membrane Oxygenation: A Review of the Current Literature.

Authors:  Jennifer Sherwin; Travis Heath; Kevin Watt
Journal:  Clin Ther       Date:  2016-08-21       Impact factor: 3.393

8.  The impact of extracorporeal life support and hypothermia on drug disposition in critically ill infants and children.

Authors:  Enno D Wildschut; Annewil van Saet; Pavla Pokorna; Maurice J Ahsman; John N Van den Anker; Dick Tibboel
Journal:  Pediatr Clin North Am       Date:  2012-08-29       Impact factor: 3.278

Review 9.  Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates.

Authors:  Marcia L Buck
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 10.  Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.

Authors:  Jessica K Roberts; Chris Stockmann; Jonathan E Constance; Justin Stiers; Michael G Spigarelli; Robert M Ward; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.